Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resista...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) Jg. 382; H. 9893; S. 700 - 708
Hauptverfasser:	Cahn, Pedro, Pozniak, Anton L, Mingrone, Horacio, Shuldyakov, Andrey, Brites, Carlos, Andrade-Villanueva, Jaime F, Richmond, Gary, Buendia, Carlos Beltran, Fourie, Jan, Ramgopal, Moti, Hagins, Debbie, Felizarta, Franco, Madruga, Jose, Reuter, Tania, Newman, Tamara, Small, Catherine B, Lombaard, John, Grinsztejn, Beatriz, Dorey, David, Underwood, Mark, Griffith, Sandy, Min, Sherene
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 24.08.2013 Elsevier Limited
Schlagworte:	Adult adults Antiretroviral agents diarrhea Double-Blind Method Drug Administration Schedule Drug dosages Drug resistance Drug Resistance, Viral Drug therapy drugs Female headache health services Heterocyclic Compounds, 3-Ring - administration & dosage Heterocyclic Compounds, 3-Ring - adverse effects HIV HIV Infections - drug therapy HIV Integrase Inhibitors - administration & dosage HIV Integrase Inhibitors - adverse effects HIV-1 Human immunodeficiency virus Human immunodeficiency virus 1 Humans Internal Medicine Male Middle Aged Mutation Patient safety patients Plasma Pyrrolidinones - administration & dosage Pyrrolidinones - adverse effects Raltegravir Potassium Respiratory tract respiratory tract diseases RNA RNA, Viral - metabolism Safety screening therapeutics Treatment Outcome Viral Load
ISSN:	0140-6736, 1474-547X, 1474-547X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!